Karolinska Institutet
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (862 trials with phase data)• Click on a phase to view related trials
Evaluation of the Wheelchair School (Drivkraft) a Clinical Study
- Conditions
- Neurological DisordersWheelchair MobilityRehabilitation
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 80
- Registration Number
- NCT07131553
- Locations
- 🇸🇪
Aleris Rehab Station, Solna, Sweden
"Airway Complications in Pediatric Patients With Tracheostomies: To What Extent Can Symptoms Identified by Caregivers or Pediatricians Serve as Predictors for Airway Complications Confirmed Through Surveillance Endoscopy?"
- Conditions
- SurveillanceEndoscopyTracheostomy ComplicationTracheostomy ComplicationsTracheostomyChildren in the Pediatric Intensive Care Unit or General Pediatric Care Unit Requiring a Central Venous Catheter
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 100
- Registration Number
- NCT07121517
- Locations
- 🇸🇪
LIVA, Barn PMI, Karolinska Universitetssjukhuset Solna, Solna, Sweden
STRONGER 60+: Assessing the Clinical Effectiveness and Delivery of an Adapted FINGER Model for Brain Health in Primary Care
- Conditions
- Older Adults at High Risk for MCIOlder Adults With Mild to Moderate Level of Dementia
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 96
- Registration Number
- NCT07117916
Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam
- Conditions
- Respiratory Distress Syndrome in Premature Infant
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 440
- Registration Number
- NCT07098910
- Locations
- 🇻🇳
Phu San Hanoi Hospital - Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam
Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies
- Conditions
- DementiaChronic Kidney DiseaseReal World StudyCognitive DeclineAcute Kidney InjuriesAlzheimer Dementia (AD)Cholinergic SystemCholinesterase Inhibitors
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 200000
- Registration Number
- NCT07093684
- Locations
- 🇸🇪
Karolinska Institutet, Stockholm, Sweden
- Prev
- 1
- 2
- 3
- 4
- 5
- 208
- Next
News
Quince Therapeutics Strengthens Scientific Advisory Board with Leading Immunologist Ahead of Phase 3 Results
Quince Therapeutics appointed Dr. Hassan Abolhassani, a top-cited immunologist from Karolinska Institutet, to its Scientific Advisory Board as the ninth expert member.
ADHD Medication Benefits Diminish as Prescription Rates Rise, Swedish Study Reveals
A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes.
Simvastatin Fails to Show Antidepressant Benefits in Major Depression and Obesity Trial
A randomized controlled trial of 161 patients with major depressive disorder and obesity found that adding simvastatin to escitalopram provided no additional antidepressant benefits compared to placebo.
Varenicline-Bupropion Combination Shows Promise for Alcohol Use Disorder Treatment
A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications.
Alamar Biosciences Partners with SciLifeLab to Advance Precision Proteomics for Early Disease Detection
Alamar Biosciences has announced a strategic collaboration with Sweden's SciLifeLab to advance translational proteomics and accelerate biomarker discovery for early disease detection.
Belimumab Shows Superior Efficacy for Systemic Lupus Erythematosus in Meta-Analysis
A comprehensive meta-analysis of five randomized controlled trials confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus (SLE) according to BICLA criteria.
Johnson & Johnson and Karolinska Institutet Celebrate Decade of Collaboration Advancing Medical Innovations
The ten-year partnership between Johnson & Johnson Innovative Medicine and Karolinska Institutet has yielded significant scientific advances across nine disease areas, with researchers working side by side since 2015.
Nanorobots for Drug Delivery Market Set to Reach $1.73 Billion by 2030, Transforming Precision Medicine
The global nanorobots for drug delivery market is projected to grow from $1.22 billion in 2025 to $1.73 billion by 2030, representing a CAGR of 7.05% as demand for targeted therapeutic solutions increases.
DiviTum® TKa Blood Test Shows Promise in Predicting Immunotherapy Response Across Multiple Cancers
New research from Karolinska Institutet demonstrates that Biovica's DiviTum® TKa blood test, when combined with inflammation protein biomarkers, significantly improves prediction of immunotherapy efficacy in melanoma patients.
Study Reveals Why Children's Cancer Immunotherapy Differs From Adults, Opening Path to Precision Medicine
Researchers at Karolinska Institutet discovered that children's tumors are less inflammatory and have fewer mutations than adults', explaining their reduced response to immunotherapy treatments.